Those of us who're truly interested in the long term viability and strength of the DCVax Platform (you obviously included) have watched all these side trials, papers, and presentations regarding the ongoing development of all kinds of peripheral enhancements that more than likely will become important augmentations in the transition from the DCVax-L success (and revenue generator) to the even more powerful Direct line.
People without the proper over view of what's occurring daily with incredibly dedicated researchers are missing the nuance of the entire business model of NWBO and the program upon which it is being built. Slow and steady wins the race.